Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Anlotinib + Sintilimab |
| Indication/Tumor Type | cervical squamous cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | cervical squamous cell carcinoma | predicted - sensitive | Anlotinib + Sintilimab | Phase II | Actionable | In a Phase II study, a combination of Anlotinib (AL-3818) and Sintilimab (IBI308) resulted in a significantly higher objective response rate in CD274 (PD-L1)-positive cervical squamous cell carcinoma patients compared to non-squamous cell cervical cancer patients, 69.7% (23/33) versus 0% (0/6), respectively (P=0.003), and longer median progression-free survival, 11.1 months vs 5.8 months, respectively (P=0.01) (PMID: 35192397). | 35192397 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (35192397) | Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial. | Full reference... |